Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Avirmax Biopharma Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners across 2 distinct art units. This structure indicates that each of the 2 pending office actions is being reviewed independently by different personnel in different administrative groups. The involvement of 2 distinct art units suggests that the company's biotechnology research is being evaluated by different specialized groups within the office.
YU, DELPHINUS DOU YI is the busiest examiner for the portfolio, with 1 pending office action. This examiner is one of the distinct examiners currently reviewing the company's pending office actions. Because each examiner is responsible for exactly one action, the workload is evenly divided. This distribution across examiners means that the company's prosecution outcomes for its 2 pending office actions are subject to the individual practices of two different examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| TAKENAKA, RISA | 1 | 26.1% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584397 | COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION | YU, DELPHINUS DOU YI | — |
| 18482767 | COMPOSITIONS AND METHODS FOR OCULAR TRANSGENE EXPRESSION | TAKENAKA, RISA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482767 | COMPOSITIONS AND METHODS FOR OCULAR TRANSGENE EXPRESSION | TAKENAKA, RISA | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18584397 | COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION | YU, DELPHINUS DOU YI | 1636 | §102§103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18482767 | COMPOSITIONS AND METHODS FOR OCULAR TRANSGENE EXPRESSION | TAKENAKA, RISA | 1632 | §101§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvirmax Biopharma Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Delphinus Dou Yi Yu has the most, with 1 of Avirmax Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
